Source: Annual Congress 2006 - Clinical aspects of tuberculosis
Disease area: Respiratory infections

Abstract

The objective of this paper is to quantify the cases of Tuberculosis in patients submitted to chronic immunosuppressive therapy for autoimmune osteoarticular disease.
19 patients with autoimmune osteoarticular disease were tested with chest roentgenogram (posteroanterior and lateral views) and tubercukin skin test (injection of Purified Protein Derivative Standart - 5 U , measured at 48 - 72 h; positive if weal greater than 5 mm). Each patient was studied regarding age, gender, rheumatic diagnosis, type of imunosupressive treatment, duration of the treatment and history of Tuberculosis and vaccination with Bacille Calmette Guerin (BCG).
The average age of the patients was 46,6 years. 84% were of the female sex.
The rheumatic diagnosis was Rheumatoid arthritis in 52% of the patients. 38% were treated with Methrotrexate, 35% with a systemic Glucocorticoid in immunosuppressive dose and 93% of the patients did combined therapy. In 50% the duration of treatment was inferior to 1 year.
11% of the patients had priors of Tuberculosis and 42% were vaccinated.
The chest roentgenogram had no abnormality in 84% of the cases and the tuberculin skin test was positive in 63%.
52% of the patients were considered infected (latent Tuberculosis) and 5% diseased.
Chronic immunosuppressive therapy is associated with increased risk of Tuberculosis, either infection or disease.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Palla Garcia, C. Gomes, A. Gomes, A. Gautier, V. Patto, A. Teixeira (Lisboa, Portugal). Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease. Eur Respir J 2006; 28: Suppl. 50, 833

Member's Comments

No comment yet.

Related content which might interest you: Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Detection of IFN-γ responses for diagnosis of tuberculosis infection in chronic inflammatory disease patients Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond Year: 2011 Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Efficacy of isoniazid preventive therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders-a retrospective cohort study in Taiwan Source: International Congress 2017 – Migrants and screening Year: 2017 Systemic corticosteroid and inhalation corticosteroid therapy are associated with nontuberculous mycobacterial pulmonary disease Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 Anti-TNF-alpha therapy in patients with latent tuberculosis incidence Source: International Congress 2015 – Screening strategies in TB Year: 2015 Evaluating the use of the interferon-γ response to mycobacterium tuberculosis (MTB) specific antigens to diagnose latent tuberculosis infection in patients with chronic inflammatory joint and skin diseases Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond Year: 2011 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Severe pulmonary infections due to biological therapy of rheumatic diseases Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies Year: 2011 Prevalence and low diagnostics of chronic non-specific pulmonary diseases among pulmonary TB patients Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007 Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs Source: Eur Respir J 2007; 30: Suppl. 51, 657s Year: 2007 Intrabronchial lymphotropic immune and antibiotic therapy in complex treatment of the chronic obstructive disease of the lung Source: Eur Respir J 2004; 24: Suppl. 48, 524s Year: 2004 Managing tuberculosis in chronic kidney disease: An evaluation of patient treatment regimens Source: Annual Congress 2011 - Tuberculosis in special populations Year: 2011 Isophonum usage in treatment of patients with pulmonary tuberculosis and accompanying pathology and elderly patients Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Clinical features of chronic pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease Source: ERJ Open Res, 8 (1) 00491-2021; 10.1183/23120541.00491-2021 Year: 2022